SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment

Summary

Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Timeline

Start

2011-08

Primary completion

2013-05

Completion

2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS are not in accordance with the scientific rank anymore.”

Drugs

Indications